54080 Federal Register / Vol. 74, No. 202 / Wednesday, October 21, 2009 / Notices 

necessary to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, for 

export requirements and the 

establishment and maintenance of 

reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by state, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $120,000,000 or more 

in any one year, and will not 

significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

This action is not a major rule as 

defined by Section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996. This action will 

not result in an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 

Dated: October 13, 2009. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. E9–25274 Filed 10–20–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[DEA # 318E] 

Controlled Substances: Established 

Initial Aggregate Production Quotas 

for 2010 

AGENCY: Drug Enforcement 

Administration (DEA), Justice. 

ACTION: Notice of aggregate production 

quotas for 2010. 

SUMMARY: This notice establishes initial 

2010 aggregate production quotas for 

controlled substances in schedules I and 

II of the Controlled Substances Act 

(CSA). 

DATES: Effective Date: October 21, 2009. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, Ph.D, Chief, 

Drug & Chemical Evaluation Section, 

Drug Enforcement Administration, 

Washington, DC 20537, Telephone: 

(202) 307–7183. 

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in schedules I and II. This responsibility 

has been delegated to the Administrator 

of the DEA by 28 CFR 0.100. The 

Administrator, in turn, has redelegated 

this function to the Deputy 

Administrator, pursuant to 28 CFR 

0.104. 

The 2010 aggregate production quotas 

represent those quantities of controlled 

substances that may be produced in the 

United States in 2010 to provide 

adequate supplies of each substance for: 

the estimated medical, scientific, 

research and industrial needs of the 

United States; lawful export 

requirements; and the establishment 

and maintenance of reserve stocks (21 

U.S.C. 826(a) and 21 CFR 1303.11). 

These quotas do not include imports of 

controlled substances for use in 

industrial processes. 

On May 21, 2009, a notice of the 

proposed initial 2010 aggregate 

production quotas for certain controlled 

substances in schedules I and II was 

published in the Federal Register (74 

FR 23881). All interested persons were 

invited to comment on or object to these 

proposed aggregate production quotas 

on or before June 22, 2009. 

Twelve responses (eleven from DEA 

registered manufacturers, and one from 

a non-DEA registrant) were received 

within the published comment period, 

offering comments on a total of 28 

schedule I and II controlled substances. 

One additional comment was received 

after the comment period ended and 

therefore was not considered. The 

commenters stated that the proposed 

aggregate production quotas for 3,4- 

methylenedioxyamphetamine, 3,4- 

methylenedioxyethylamphetamine, 3,4- 

methylenedioxymethamphetamine, 

alfentanil, amphetamine (for sale), 

codeine (for sale), codeine (for 

conversion), dihydromorphine, 

fentanyl, gamma hydroxybutyric acid, 

hydrocodone, hydromorphone, 

isomethadone, levo-desoxyephedrine, 

levorphanol, lisdexamfetamine, 

methamphetamine (for sale), morphine 

(for conversion), nabilone, opium 

(tincture), oxycodone (for sale), 

oxycodone (for conversion), 

oxymorphone (for sale), remifentanil, 

sufentanil, tapentadol, 

tetrahydrocannabinols, and thebaine 

were insufficient to provide for the 

estimated medical, scientific, research 

and industrial needs of the United 

States, for export requirements and for 

the establishment and maintenance of 

reserve stocks. 

In arriving at the aggregate production 

quotas, DEA has taken into 

consideration the above comments 

along with the factors set forth at 21 

CFR 1303.11(b) and other relevant 2009 

factors, including 2009 manufacturing 

quotas, current 2009 sales and 

inventories, 2010 export requirements, 

additional applications received, and 

research and product development 

requirements. Based on this 

information, DEA has adjusted the 

initial aggregate production quotas for 4- 

methoxyamphetamine, alphamethyltryptamine, amphetamine (for 

conversion), dihydromorphine, 

isomethadone, levo-desoxyephedrine, 

lisdexamfetamine, lysergic acid 

diethylamide, methamphetamine (for 

sale), methamphetamine (for 

conversion), methaqualone, oxycodone 

(for sale), oxycodone (for conversion), 

oxymorphone (for sale) and 

phenylacetone to meet the legitimate 

needs of the United States. 

DEA proposed the aggregate 

production quota for tapentadol at 

519,000 g in the 2010 proposed initial 

aggregate production quota notice 

published on May 21, 2009 in the 

Federal Register (74 FR 23881). 

Tapentadol is no longer listed because 

the material will be imported into the 

United States and not manufactured 

domestically. 

Regarding 3,4- 

methylenedioxyamphetamine, 3,4- 

methylenedioxyethylamphetamine, 3,4- 

methylenedioxymethamphetamine, 

alfentanil, amphetamine (for sale), 

codeine (for sale), codeine (for 

conversion), fentanyl, gamma 

hydroxybutyric acid, hydrocodone, 

hydromorphone, levorphanol, morphine 

(for conversion), nabilone, opium 

(tincture), remifentanil, sufentanil, 

tetrahydrocannabinols, and thebaine 

DEA has determined that the proposed 

initial 2010 aggregate production quotas 

are sufficient to meet the current 2010 

estimated medical, scientific, research 

and industrial needs of the United 

States. 

Pursuant to 21 CFR 1303, the Deputy 

Administrator of DEA will, in 2010, 

adjust aggregate production quotas and 

individual manufacturing quotas 

allocated for the year based upon 2009 

year-end inventory and actual 2009 

disposition data supplied by quota 

recipients for each basic class of 

schedule I or II controlled substance. 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 202 / Wednesday, October 21, 2009 / Notices 54081 

Therefore, under the authority vested 

in the Attorney General by Section 306 

of the CSA (21 U.S.C. 826), and 

delegated to the Administrator of DEA 

by 28 CFR § 0.100, and redelegated to 

the Deputy Administrator pursuant to 

28 CFR 0.104, the Deputy Administrator 

hereby orders that the 2010 initial 

aggregate production quotas for the 

following controlled substances, 

expressed in grams of anhydrous acid or 

base, be established as follows: 

Basic class—Schedule I Established 2010 quotas 

2,5-Dimethoxyamphetamine ...................................................................................................................................... 2 g 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ............................................................................................................ 2 g 

3-Methylfentanyl ......................................................................................................................................................... 2 g 

3-Methylthiofentanyl ................................................................................................................................................... 2 g 

3,4-Methylenedioxyamphetamine (MDA) .................................................................................................................. 25 g 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ................................................................................................... 10 g 

3,4-Methylenedioxymethamphetamine (MDMA) ....................................................................................................... 20 g 

3,4,5-Trimethoxyamphetamine .................................................................................................................................. 2 g 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ............................................................................................................ 2 g 

4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ....................................................................................................... 2 g 

4-Methoxyamphetamine ............................................................................................................................................ 77 g 

4-Methylaminorex ...................................................................................................................................................... 2 g 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ............................................................................................................ 2 g 

5-Methoxy-3,4-methylenedioxyamphetamine ............................................................................................................ 2 g 

5-Methoxy-N,N-diisopropyltryptamine ........................................................................................................................ 5 g 

Acetyl-alpha-methylfentanyl ....................................................................................................................................... 2 g 

Acetyldihydrocodeine ................................................................................................................................................. 2 g 

Acetylmethadol .......................................................................................................................................................... 2 g 

Allylprodine ................................................................................................................................................................ 2 g 

Alphacetylmethadol .................................................................................................................................................... 2 g 

Alpha-ethyltryptamine ................................................................................................................................................ 2 g 

Alphameprodine ......................................................................................................................................................... 2 g 

Alphamethadol ........................................................................................................................................................... 2 g 

Alpha-methylfentanyl ................................................................................................................................................. 2 g 

Alpha-methylthiofentanyl ............................................................................................................................................ 2 g 

Alpha-methyltryptamine ............................................................................................................................................. 2 g 

Aminorex .................................................................................................................................................................... 2 g 

Benzylmorphine ......................................................................................................................................................... 2 g 

Betacetylmethadol ..................................................................................................................................................... 2 g 

Beta-hydroxy-3-methylfentanyl .................................................................................................................................. 2 g 

Beta-hydroxyfentanyl ................................................................................................................................................. 2 g 

Betameprodine ........................................................................................................................................................... 2 g 

Betamethadol ............................................................................................................................................................. 2 g 

Betaprodine ................................................................................................................................................................ 2 g 

Bufotenine .................................................................................................................................................................. 3 g 

Cathinone ................................................................................................................................................................... 3 g 

Codeine-N-oxide ........................................................................................................................................................ 602 g 

Diethyltryptamine ....................................................................................................................................................... 2 g 

Difenoxin .................................................................................................................................................................... 3,000 g 

Dihydromorphine ........................................................................................................................................................ 3,300,000 g 

Dimethyltryptamine .................................................................................................................................................... 3 g 

Gamma-hydroxybutyric acid ...................................................................................................................................... 24,200,000 g 

Heroin ........................................................................................................................................................................ 20 g 

Hydromorphinol .......................................................................................................................................................... 2 g 

Hydroxypethidine ....................................................................................................................................................... 2 g 

Ibogaine ..................................................................................................................................................................... 1 g 

Lysergic acid diethylamide (LSD) .............................................................................................................................. 15 g 

Marihuana .................................................................................................................................................................. 4,500,000 g 

Mescaline ................................................................................................................................................................... 7 g 

Methaqualone ............................................................................................................................................................ 7 g 

Methcathinone ........................................................................................................................................................... 4 g 

Methyldihydromorphine .............................................................................................................................................. 2 g 

Morphine-N-oxide ...................................................................................................................................................... 605 g 

N-Benzylpiperazine .................................................................................................................................................... 2 g 

N,N-Dimethylamphetamine ........................................................................................................................................ 7 g 

N-Ethylamphetamine ................................................................................................................................................. 2 g 

N-Hydroxy-3,4-methylenedioxyamphetamine ............................................................................................................ 2 g 

Noracymethadol ......................................................................................................................................................... 2 g 

Norlevorphanol ........................................................................................................................................................... 52 g 

Normethadone ........................................................................................................................................................... 2 g 

Normorphine .............................................................................................................................................................. 16 g 

Para-fluorofentanyl ..................................................................................................................................................... 2 g 

Phenomorphan .......................................................................................................................................................... 2 g 

Pholcodine ................................................................................................................................................................. 2 g 

Psilocybin ................................................................................................................................................................... 7 g 

Psilocyn ...................................................................................................................................................................... 7 g 

Tetrahydrocannabinols .............................................................................................................................................. 312,500 g 

Thiofentanyl ............................................................................................................................................................... 2 g 

Trimeperidine ............................................................................................................................................................. 2 g 


jlentini on DSKJ8SOYB1PROD with NOTICES
54082 Federal Register / Vol. 74, No. 202 / Wednesday, October 21, 2009 / Notices 

Basic class—Schedule II Established 2010 quotas 

1-Phenylcyclohexylamine .......................................................................................................................................... 2 g 

1-piperdinocyclohexanecarbonitrile ........................................................................................................................... 2 g 

Alfentanil .................................................................................................................................................................... 8,000 g 

Alphaprodine .............................................................................................................................................................. 2 g 

Amobarbital ................................................................................................................................................................ 3 g 

Amphetamine (for sale) ............................................................................................................................................. 17,000,000 g 

Amphetamine (for conversion) .................................................................................................................................. 6,500,000 g 

Cocaine ...................................................................................................................................................................... 247,000 g 

Codeine (for sale) ...................................................................................................................................................... 39,605,000 g 

Codeine (for conversion) ........................................................................................................................................... 65,000,000 g 

Dextropropoxyphene .................................................................................................................................................. 106,000,000 g 

Dihydrocodeine .......................................................................................................................................................... 1,200,000 g 

Diphenoxylate ............................................................................................................................................................ 947,000 g 

Ecgonine .................................................................................................................................................................... 83,000 g 

Ethylmorphine ............................................................................................................................................................ 2 g 

Fentanyl ..................................................................................................................................................................... 1,428,000 g 

Glutethimide ............................................................................................................................................................... 2 g 

Hydrocodone (for sale) .............................................................................................................................................. 55,000,000 g 

Hydromorphone ......................................................................................................................................................... 3,300,000 g 

Isomethadone ............................................................................................................................................................ 11 g 

Levo-alphacetylmethadol (LAAM) .............................................................................................................................. 3 g 

Levomethorphan ........................................................................................................................................................ 5 g 

Levorphanol ............................................................................................................................................................... 10,000 g 

Lisdexamfetamine ...................................................................................................................................................... 9,000,000 g 

Meperidine ................................................................................................................................................................. 8,600,000 g 

Meperidine Intermediate-A ........................................................................................................................................ 3 g 

Meperidine Intermediate-B ........................................................................................................................................ 7 g 

Meperidine Intermediate-C ........................................................................................................................................ 3 g 

Metazocine ................................................................................................................................................................. 1 g 

Methadone (for sale) ................................................................................................................................................. 25,000,000 g 

Methadone Intermediate ............................................................................................................................................ 26,000,000 g 

Methamphetamine ..................................................................................................................................................... 3,130,000 g 

[750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 grams for methamphetamine 

mostly for conversion to a schedule III product; and 49,000 grams for methamphetamine (for sale)] 

Methylphenidate ......................................................................................................................................................... 50,000,000 g 

Morphine (for sale) .................................................................................................................................................... 35,000,000 g 

Morphine (for conversion) .......................................................................................................................................... 100,000,000 g 

Nabilone ..................................................................................................................................................................... 9,002 g 

Noroxymorphone (for sale) ........................................................................................................................................ 10,000 g 

Noroxymorphone (for conversion) ............................................................................................................................. 9,000,000 g 

Opium (powder) ......................................................................................................................................................... 230,000 g 

Opium (tincture) ......................................................................................................................................................... 1,050,000 g 

Oripavine .................................................................................................................................................................... 15,000,000 g 

Oxycodone (for sale) ................................................................................................................................................. 88,000,000 g 

Oxycodone (for conversion) ...................................................................................................................................... 4,000,000 g 

Oxymorphone (for sale) ............................................................................................................................................. 2,570,000 g 

Oxymorphone (for conversion) .................................................................................................................................. 12,000,000 g 

Pentobarbital .............................................................................................................................................................. 28,000,000 g 

Phenazocine .............................................................................................................................................................. 1 g 

Phencyclidine ............................................................................................................................................................. 20 g 

Phenmetrazine ........................................................................................................................................................... 2 g 

Phenylacetone ........................................................................................................................................................... 12,500,001 g 

Racemethorphan ....................................................................................................................................................... 2 g 

Remifentanil ............................................................................................................................................................... 500 g 

Secobarbital ............................................................................................................................................................... 67,000 g 

Sufentanil ................................................................................................................................................................... 10,300 g 

Thebaine .................................................................................................................................................................... 126,000,000 g 

The Deputy Administrator further 

orders that aggregate production quotas 

for all other schedules I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 be established 

at zero. 

The Office of Management and Budget 

has determined that notices of aggregate 

production quotas are not subject to 

centralized review under Executive 

Order 12866. This action does not 

preempt or modify any provision of 

state law; nor does it impose 

enforcement responsibilities on any 

state; nor does it diminish the power of 

any state to enforce its own laws. 

Accordingly, this action does not have 

federalism implications warranting the 

application of Executive Order 13132. 

The Deputy Administrator hereby 

certifies that this action will have no 

significant impact upon small entities 

whose interests must be considered 

under the Regulatory Flexibility Act, 5 

U.S.C. 601 et seq. The establishment of 

aggregate production quotas for 

schedules I and II controlled substances 

is mandated by law and by international 

treaty obligations. The quotas are 

necessary to provide for the estimated 

medical, scientific, research and 

industrial needs of the United States, for 

export requirements and the 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 202 / Wednesday, October 21, 2009 / Notices 54083 

establishment and maintenance of 

reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by State, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $120,000,000 or more 

in any one year, and will not 

significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

This action is not a major rule as 

defined by Section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996. This action will 

not result in an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 

Dated: October 14, 2009. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. E9–25275 Filed 10–20–09; 8:45 am] 

BILLING CODE 4410–09–P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice (09–091)] 

NASA Advisory Council; Meeting 

AGENCY: National Aeronautics and 

Space Administration. 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, Public 

Law 92–463, as amended, the National 

Aeronautics and Space Administration 

announces a meeting of the National 

Space-Based Positioning, Navigation 

and Timing (PNT) Advisory Board. 

DATES: Thursday, November 5, 2009, 9 

a.m.–5 p.m.; Friday, November 6, 2009, 

9 a.m.–1 p.m. 

ADDRESSES: Hilton Old Town 

Alexandria, 1767 King Street, 

Alexandria, Virginia 22314. Metro 

Station: King Street. 

FOR FURTHER INFORMATION CONTACT: Mr. 

James J. Miller, Space Operations 

Mission Directorate, National 

Aeronautics and Space Administration, 

Washington, DC 20546. Phone 202–358– 

4417. 

SUPPLEMENTARY INFORMATION: The 

agenda for the meeting includes updates 

from each of the three PNT Panels 

(Leadership; Strategic Engagement; and 

Communication, Future Challenges), 

including discussion and deliberation of 

potential recommendations. The PNT 

Advisory Board will address U.S. 

Government interests in the following 

areas: 

• Implementation of the President’s 

2004 U.S. Space-Based Positioning, 

Navigation and Timing Policy. 

• National Space-Based PNT 

Executive Committee, and National 

Space-Based PNT Coordination Office. 

• Global Positioning System (GPS) 

Constellation and Modernization Plans. 

• U.S. GPS Technological Leadership 

and Competitiveness. 

• Promoting and Branding Current 

and Future PNT Capabilities to the U.S. 

and International Communities. 

• Global Technical and Market 

Trends for PNT Services. 

• Future Areas of Study. 

The meeting will be open to the public 

up to the seating capacity of the room. 

It is imperative that the meeting be held 

on this date to accommodate the 

scheduling priorities of the key 

participants. 

P. Diane Rausch, 

Advisory Committee Management Officer, 

National Aeronautics and Space 

Administration. 

[FR Doc. E9–25351 Filed 10–20–09; 8:45 am] 

BILLING CODE 7510–13–P 

NATIONAL ARCHIVES AND RECORDS 

ADMINISTRATION 

Advisory Committee on the Electronic 

Records Archives 

AGENCY: National Archives and Records 

Administration. 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), the 

National Archives and Records 

Administration (NARA) announces a 

meeting of the Advisory Committee on 

the Electronic Records Archives 

(ACERA). The committee serves as a 

deliberative body to advise the Archivist 

of the United States, on technical, 

mission, and service issues related to 

the Electronic Records Archives (ERA). 

This includes, but is not limited to, 

advising and making recommendations 

to the Archivist on issues related to the 

development, implementation and use 

of the ERA system. 

DATES: November 4–5, 2009, 9 a.m. to 4 

p.m. 

ADDRESSES: 700 Pennsylvania Avenue, 

NW. Washington, DC 20408–0001. 

SUPPLEMENTARY INFORMATION: 

Agenda 

• Opening Remarks; 

• Approval of Minutes; 

• Committee Updates; 

• Activities Reports; 

• Adjournment. 

This meeting will be open to the 

public. However, due to space 

limitations and access procedures, the 

name and telephone number of 

individuals planning to attend must be 

submitted to the Electronic Records 

Archives Program at 

era.program@nara.gov. This meeting 

will be recorded for transcription 

purposes. 

FOR FURTHER INFORMATION CONTACT: 

Martha Morphy, Assistant Archivist for 

Information Services, (301) 837–1992. 

Dated: October 15, 2009. 

Mary Ann Hadyka, 

Committee Management Officer. 

[FR Doc. E9–25368 Filed 10–20–09; 8:45 am] 

BILLING CODE 7515–01–P 

National Labor Relations Board 

Appointments of Individuals To Serve 

as Members of Performance Review 

Board 

5 U.S.C. 4314(c)(4) requires that 

appointments of individuals to serve as 

members of Performance Review Boards 

be published in the Federal Register. 

Therefore, in compliance with this 

requirement, notice is hereby given that 

the individuals whose names and 

position titles appear below have been 

appointed to serve as members of 

Performance Review Boards in the 

National Labor Relations Board for the 

rating year beginning October 1, 2008 

and ending September 30, 2009. 

Name and Title 

William B Cowen, Solicitor; 

Gloria J. Joseph, Director of 

Administration; 

Barry J. Kearney, Associate General 

Counsel, Advice; 

Gary W. Shinners, Deputy Chief 

Counsel to Board Member; 

Richard A. Siegel, Associate General 

Counsel, Operations Management; 

Lafe E. Solomon, Director, Office of 

Representation Appeals; 


jlentini on DSKJ8SOYB1PROD with NOTICES